

Education Needed on Opioid Prescription Regs

BY MARY ELLEN SCHNEIDER
New York Bureau

NEW ORLEANS — Get educated about state and federal regulations and policies on the prescription of controlled substances, advised David Joranson, director of the Pain and Policy Studies Group at the University of Wisconsin Paul P. Carbone Comprehensive Cancer Center in Madison.

Mr. Joranson, who spoke at the annual meeting of the American Academy of

Pain Medicine, said that understanding current regulations is critical to avoiding unnecessary fears over the risk of sanctions from prescribing pain medication.

In recent years there has been increasing agreement reached between pain medicine specialists, law enforcement, and regulators, he said.

For example, from 2003 to 2006, 19 states either repealed or added language to their state's controlled substances prescribing policies to take a more balanced

approach—recognizing opioids are necessary but also pose risks and need to be controlled.

"The state policies are becoming more balanced," he said.

Importantly, 39 states have adopted a policy aimed at directly addressing physicians' concerns about regulatory scrutiny, he added.

Nearly 10 years ago, the Federation of State Medical Boards made it clear that physicians should recognize that toler-

ance and physical dependence are the normal consequences of the sustained use of opioid analgesics and are not synonymous with addiction. As a result, many state medical board guidelines now reflect that statement, Mr. Joranson said.

Last year, at the federal level the Drug Enforcement Administration issued a statement that nearly every prescription issued in the United States is for a legitimate medical purpose and that the amount of dosage units per prescription will never be a basis for investigation for the overwhelming majority of physicians.

"Here again it looks like we're pretty much on the same page," he said.

Research findings indicated, however, that physicians may not be paying attention to this policy shift. In a study published in the *Journal of Family Practice* in 2001, investigators from the University of California, San Francisco/Stanford Collaborative Research Network surveyed 230 primary care physicians on pain treatment, the use of opioids, and their familiarity with state prescribing and documentation guidelines.

Specifically, the investigation focused on whether physicians were aware of guidelines on prescribing opioids for chronic nonmalignant pain that were issued by the Medical Board of California in 1994. The guidelines were aimed in part at reducing physicians' fear of regulatory scrutiny. The guidelines were mailed to all licensed physician in the state three times between 1994 and 1996.

Of the 161 physicians who completed the survey, only 39% remembered reading the guidelines 1 year after the third mailing. And 40% of respondents said that fear of legal investigation influenced their opioid prescribing habits.

"It can be an uphill battle to get physicians to pay attention to policy," Mr. Joranson said. ■

INDEX OF ADVERTISERS

Archer Daniels Midland Company	
NovaSoy	13
Bayer HealthCare Pharmaceuticals Inc.	
Yaz	3-4
Mirena	23-24
Angeliq	30a-30b, 31
Conceptus Incorporated	
Essure	25
Discovery Health	
CME	5
Duramed Pharmaceuticals, Inc. (a subsidiary of Barr Pharmaceuticals)	
ParaGard	14a-14b
ETHICON, Inc.	
Gynecare TVT Secur	17
GlaxoSmithKline	
Twinrix	19-20
McNeil-PPC, Inc.	
Monistat	21
Merck & Co., Inc.	
Fosamax Plus D	11
Organon USA Inc.	
NuvaRing	9-10
Pfizer Inc.	
Her Pfizer	7
Detrol LA	26-28
Wyeth Consumer Healthcare	
Caltrate	44

Take our temperature.

Which ads are hot?

Check our pulse.

Which ads make your heart beat faster?

Make your diagnosis.

Give medical journal ads from 2006 a thorough online examination, and help enhance the quality of healthcare advertising.

Point, click & vote at www.docvote.com

The Association of Medical Publications **AMP**